Newsroom | 71202 results

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI model for tumor and immune biology, today announced that nine abstracts have been accepted at the 2026 ASCO Annual Meeting (ASCO), scheduled to take place May 30 – June 2, 2026, at McCormick Place Convention Center in Chicago, IL. BostonGene will also exhibit at booth #33137. The accepted abstracts underscore the broad clinical utility of BostonGene’s AI-powered models and advanced analytical platforms, including the Tumor...

HYOGO, Japan--(BUSINESS WIRE)--JCR announced that it will present new clinical data in a poster session at the 18th International Symposium on MPS and Related Lysosomal Diseases....

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced new post hoc, exploratory analyses from two identical Phase 3 clinical trials evaluating centanafadine, an investigational, first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), in adults with attention-deficit hyperactivity disorder (ADHD). The data, presented at the 2026 American Society of Clinical...

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced plans to launch advanced digital solutions to equip healthcare providers with personalized patient insights at the point of care. Through a seamless integration with Roche’s navify Clinical Hub, a disease management solution for collaborative care teams, Foundation Medicine will soon provide U.S.-based healthcare providers with customized digital tools to help navigate compl...

PALO ALTO, Calif.--(BUSINESS WIRE)--Hexo Labs has developed the world’s first agent that learns from itself instead of human actions, rapidly increasing the speed of improvement....

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Evecxia Therapeutics, Inc.—a clinical-stage neuroscience company developing a novel class of Serotonin Synthesis Amplification therapies—today announced the publication of the peer-reviewed article titled “Serotonin Synthesis Amplification to Augment the Therapeutic Efficacy of Serotonin Reuptake Inhibitor Antidepressants - Five Decades of Clinical Evidence” in the Journal of Clinical Psychopharmacology. The review article was co-authored with Dr....

CHICAGO--(BUSINESS WIRE)--Massive Bio, a global leader in AI-enabled oncology trial access and precision oncology navigation, today announced that it will unveil the next phase of Reticulum Nexus™, its trusted multi-agent oncology intelligence ecosystem, during the 2026 American Society of Clinical Oncology Annual Meeting in Chicago. Reticulum Nexus is designed to address one of oncology’s most persistent failures: the gap between the rapid pace of cancer innovation and the ability of patients,...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Augurex’s SPINEstat® blood test for axial spondyloarthritis is a finalist for the ADLM 2026 Disruptive Technology Award, a major industry recognition....

WASHINGTON--(BUSINESS WIRE)--Soon, schools across the country let out for summer. For tens of millions of kids, that means significantly more time on phones, tablets, gaming consoles, and apps their parents may never have heard of. For most families, it also means heading into the season underprepared for what their kids are actually encountering online. Today, Stanford Social Media Lab, in collaboration with the Family Online Safety Institute (FOSI) and California Partners Project, released A...

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that Stefan Weber, CEO and Roberto Galli, CFO, will participate in the following investor conferences in June: Jefferies Global Healthcare Conference, June 2–4, 2026, New York H.C. Wainwright 7th Annual Neuro Perspectives...